Breaking News, Collaborations & Alliances

DSM, DecImmune In Antibody Development Pact

Will provide development activities for monoclonal antibody program

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Pharmaceutical Products has signed an agreement with DecImmune Therapeutics for the initiation of development activities for DecImmune’s lead monoclonal antibody therapeutic designed to reduce tissue damage and improve ventricular function associated with myocardial infarction. Financial terms were not disclosed.   The initial development will be performed at DSM Biologics’ Groningen facility in the Netherlands, with the objective of progressing manufacture of clinical trial mate...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters